LRI Investments LLC Buys 572 Shares of Edwards Lifesciences Co. (NYSE:EW)

LRI Investments LLC lifted its stake in Edwards Lifesciences Co. (NYSE:EW) by 4.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 14,528 shares of the medical research company’s stock after purchasing an additional 572 shares during the period. LRI Investments LLC’s holdings in Edwards Lifesciences were worth $1,076,000 as of its most recent SEC filing.

A number of other large investors have also recently modified their holdings of EW. Crowley Wealth Management Inc. bought a new position in Edwards Lifesciences in the fourth quarter worth about $26,000. Millstone Evans Group LLC bought a new stake in Edwards Lifesciences during the 4th quarter valued at approximately $29,000. Migdal Insurance & Financial Holdings Ltd. purchased a new position in shares of Edwards Lifesciences during the 4th quarter worth approximately $30,000. Roble Belko & Company Inc bought a new position in shares of Edwards Lifesciences in the 4th quarter worth approximately $46,000. Finally, Catalyst Capital Advisors LLC purchased a new position in shares of Edwards Lifesciences in the 4th quarter valued at approximately $54,000. Institutional investors own 79.46% of the company’s stock.

Insider Buying and Selling

In other news, VP Donald E. Bobo, Jr. sold 6,500 shares of the company’s stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $75.75, for a total transaction of $492,375.00. Following the completion of the sale, the vice president now owns 46,936 shares of the company’s stock, valued at $3,555,402. This represents a 12.16% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Scott B. Ullem sold 11,250 shares of the stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $75.76, for a total transaction of $852,300.00. Following the completion of the transaction, the chief financial officer now owns 30,561 shares in the company, valued at $2,315,301.36. This trade represents a 26.91% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 89,681 shares of company stock worth $6,492,703. 1.29% of the stock is owned by insiders.

Analyst Ratings Changes

EW has been the topic of several research reports. Barclays lifted their price target on Edwards Lifesciences from $88.00 to $90.00 and gave the company an “overweight” rating in a research report on Thursday, February 13th. Evercore ISI cut their price objective on shares of Edwards Lifesciences from $75.00 to $73.00 and set an “in-line” rating on the stock in a report on Wednesday, February 12th. Morgan Stanley raised their target price on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the company an “equal weight” rating in a research note on Wednesday, February 12th. Stifel Nicolaus raised Edwards Lifesciences from a “hold” rating to a “buy” rating and boosted their price target for the stock from $75.00 to $90.00 in a research report on Thursday, January 30th. Finally, Truist Financial cut their price target on Edwards Lifesciences from $78.00 to $75.00 and set a “hold” rating on the stock in a research note on Friday, April 11th. One equities research analyst has rated the stock with a sell rating, twelve have assigned a hold rating and twelve have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $79.45.

Edwards Lifesciences Trading Down 1.1%

Edwards Lifesciences stock opened at $73.82 on Monday. Edwards Lifesciences Co. has a one year low of $58.93 and a one year high of $95.25. The business’s fifty day moving average is $71.48 and its 200 day moving average is $71.51. The stock has a market capitalization of $43.40 billion, a PE ratio of 10.59, a price-to-earnings-growth ratio of 4.82 and a beta of 1.12. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.60 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. The firm had revenue of $1.41 billion for the quarter, compared to the consensus estimate of $1.40 billion. During the same quarter last year, the firm posted $0.66 EPS. The business’s quarterly revenue was up 6.2% compared to the same quarter last year. On average, sell-side analysts predict that Edwards Lifesciences Co. will post 2.45 EPS for the current year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.